Death by Blood Pressure Pill? Forensic Study Maps When Amlodipine Turns Lethal

Amlodipine is one of the most widely prescribed drugs in the world, a calcium channel blocker taken daily by millions of people to keep their blood pressure under control. In therapeutic doses it is remarkably safe, gently relaxing the smooth muscle of blood vessels and easing the workload on the heart. But in overdose, the same drug can push the cardiovascular system into catastrophic failure, producing cardiogenic shock, profound tissue hypoperfusion and progressive damage to the organs that depend on a steady supply of oxygenated blood. For forensic toxicologists, this creates a persistent and consequential problem: when amlodipine is found in the blood of a deceased person, how much of the drug is too much? A new retrospective study of 33 autopsy cases, published in the International Journal of Legal Medicine, offers the clearest quantitative answer yet, and in doing so exposes a phenomenon that has long complicated death investigation worldwide.

The research, led by Alice Matheux and colleagues at the Dijon University Hospital in France, set out to define postmortem reference concentrations for amlodipine, distinguishing levels compatible with harmless therapeutic exposure from those that may have contributed to death. The team reviewed 33 autopsy cases in which amlodipine had been quantified in postmortem jugular vein blood. Crucially, the classification of each case was made on the basis of autopsy findings and circumstantial evidence, deliberately independent of the measured amlodipine concentration, to avoid circular reasoning. Cases were assigned to one of two groups: deaths that were amlodipine-related or possibly related, designated G1, and deaths clearly unrelated to the drug, designated G2. This design allowed the researchers to compare the concentration distributions of the two groups statistically and to derive tentative interpretive thresholds from the boundary between them.

The analytical backbone of the study was a validated liquid chromatography coupled with high-resolution mass spectrometry method, abbreviated LC-HRMS. This technique separates the drug from the complex matrix of decomposing blood and then identifies and quantifies it by its exact mass and fragmentation pattern, offering specificity that older immunoassay or low-resolution methods cannot match. High-resolution mass spectrometry has become a cornerstone of modern forensic toxicology precisely because it can confirm molecular identity with near-certainty, reducing the risk of false positives that could unfairly implicate a medication in someone’s death. Once concentrations were obtained, the two groups were compared using a two-tailed Student’s t-test, a standard parametric test for assessing whether the means of two datasets differ beyond what random variation would predict.

The results were striking. Of the 33 cases, 16 fell into the amlodipine-related or possibly related group, with a median postmortem blood concentration of 115 micrograms per liter, and an interquartile range running from 85.5 to 255.5 micrograms per liter. The 17 unrelated deaths in the comparison group showed a median of just 41 micrograms per liter, with a first quartile of 31 and a third quartile of 87 micrograms per liter. The difference between the groups was statistically significant, with a p-value of 0.01, meaning there is roughly a one percent probability that a gap of this size would arise by chance if the two groups were truly drawn from the same distribution. From these figures, the authors proposed practical interpretive boundaries for casework.

According to the study, postmortem whole blood concentrations below approximately 90 micrograms per liter, and more precisely below 87 micrograms per liter based on their data, appear compatible with non-toxic exposure to amlodipine. Conversely, concentrations above roughly 250 to 300 micrograms per liter, with 255.5 micrograms per liter marking the threshold in their dataset, may indicate toxicity that contributed to death. These numbers may seem abstract, but they carry enormous weight in courtrooms and inquest rooms, where a toxicologist’s interpretation of a single blood concentration can determine whether a death is ruled accidental, suicidal, natural or suspicious. Between the two thresholds lies a gray zone where interpretation must lean heavily on autopsy findings, scene investigation and medical history.

Yet the study’s most conceptually important finding concerns not the lethal threshold but the apparently benign one. In the group of amlodipine-unrelated deaths, the median concentration of 41 micrograms per liter was 2.73 times higher than the therapeutic plasma concentrations observed in living patients, which typically range from 3 to 15 micrograms per liter. In other words, people who died of entirely unrelated causes, and who were presumably taking amlodipine at prescribed doses, showed postmortem blood levels that would look alarming if judged by clinical standards. A naive reading of such a result could wrongly suggest drug toxicity in a death that had nothing to do with the medication, or conversely could erode confidence in the entire interpretive framework.

The explanation lies in a phenomenon known as postmortem redistribution. After death, the body’s circulatory and cellular systems gradually break down, and drugs that had been concentrated in tissues begin to leak back into the blood. Organs such as the lungs, liver and myocardium act as reservoirs for certain compounds, particularly basic, lipophilic drugs that bind to acidic phospholipids in cell membranes. Amlodipine, with its long half-life and large volume of distribution, is a textbook candidate for this process. As tissue stores equilibrate with blood after death, concentrations in sampled blood can rise substantially above anything the living body ever experienced. The published blood-to-plasma ratio for amlodipine, described as 1.48 or 1.7 depending on the reference, does not fully account for the observed elevation, which points toward redistribution as the dominant mechanism.

Postmortem redistribution is one of the most treacherous pitfalls in forensic toxicology, and it is not unique to amlodipine. Drugs as diverse as digoxin, tricyclic antidepressants and many antipsychotics show similar postmortem drift, which is why forensic guidelines generally recommend sampling blood from peripheral sites such as the femoral vein, where redistribution tends to be less pronounced. The Dijon team sampled jugular vein blood, a central site more susceptible to redistribution effects, which the authors acknowledge as a consideration. Autopsy findings associated with elevated amlodipine concentrations have been described in the literature, and the new dataset adds weight to the argument that direct extrapolation from living therapeutic ranges to postmortem measurements is fundamentally unreliable for this drug.

The practical implications ripple outward from the mortuary. Emergency physicians know amlodipine overdose as a feared presentation, capable of producing refractory vasodilatory shock that resists standard resuscitation and has historically required unconventional measures such as high-dose insulin-glucose therapy. Fatalities from intentional and accidental overdose, including cases involving infants and elderly patients, have been documented for decades. But proving that amlodipine caused a particular death requires reliable concentration benchmarks, and until now, forensic practitioners have had to rely on scattered case reports and small series. By providing group-based medians and quartiles from systematically classified cases, the French team has given toxicologists a defensible starting point for interpretation, one anchored in the reality of postmortem chemistry rather than the pharmacology of the living.

The authors are careful to frame their conclusions as provisional. Thirty-three cases, while a meaningful addition to the literature, remain a modest sample, and the overlap between the two groups means individual concentrations near the thresholds cannot be interpreted in isolation. They call for further large-scale, multicenter studies to establish validated postmortem reference ranges for amlodipine, ideally incorporating peripheral blood sampling, tissue measurements and standardized case classification across institutions. Until such datasets exist, the Dijon results stand as both a warning and a tool: a warning that postmortem blood levels of this common medication can be dramatically inflated by the chemistry of death itself, and a tool that, used alongside autopsy findings and clinical context, helps distinguish the patient who died despite their blood pressure pills from the one who died because of them.

Subject of Research: Postmortem amlodipine concentrations and postmortem redistribution in forensic toxicology

Article Title: Postmortem amlodipine concentrations and postmortem redistribution: a retrospective study of 33 cases

Article References: Matheux, A., Amadieu, C., Pasquet, A., François-Purssell, I., Loiseau, M., & Guerard, P. (2026). Postmortem amlodipine concentrations and postmortem redistribution: a retrospective study of 33 cases. International Journal of Legal Medicine. https://doi.org/10.1007/s00414-026-04014-6

Image Credits: AI Generated

DOI: 10.1007/s00414-026-04014-6

Keywords: amlodipine, forensic toxicology, postmortem redistribution, LC-HRMS, calcium channel blocker, autopsy, blood concentration thresholds, cardiogenic shock, pharmacokinetics, legal medicine, drug overdose, postmortem blood analysis